NZ704905B2 - Protein material comprising angiogenin and cystatin - Google Patents

Abstract

The present invention addresses the problem of providing a safe and novel protein material which is useful in the prevention and treatment of various bone disorders such as osteoporosis, bone fractures, rheumatism, and arthritis when taken on a daily basis. The present invention also addresses the problem of providing bone-strengthening food and beverages or feed which is useful in the prevention and treatment of various bone disorders such as osteoporosis, bone fractures, rheumatism, and arthritis when taken orally. A protein material containing 2 to 15 mg/100 mg of angiogenin and/or an angiogenin degradation product, and cystatin and/or a cystatin degradation product at a mass ratio of 0.003 to 0.6 relative to the angiogenin and/or angiogenin degradation product. It is possible to strengthen bones and to prevent and treat various bone disorders such as osteoporosis, bone fractures, rheumatism, and arthritis by taking said protein material. roblem of providing bone-strengthening food and beverages or feed which is useful in the prevention and treatment of various bone disorders such as osteoporosis, bone fractures, rheumatism, and arthritis when taken orally. A protein material containing 2 to 15 mg/100 mg of angiogenin and/or an angiogenin degradation product, and cystatin and/or a cystatin degradation product at a mass ratio of 0.003 to 0.6 relative to the angiogenin and/or angiogenin degradation product. It is possible to strengthen bones and to prevent and treat various bone disorders such as osteoporosis, bone fractures, rheumatism, and arthritis by taking said protein material.

Description

SNOW-191 N MATERIAL COMPRISING ENIN AND CYSTATIN TECHNICAL FIELD This invention relates to a novel protein material, and a drug, food, drink, or feed that includes the protein al and is useful for prevention and treatment of bone diseases. The protein material has functions of promoting osteoblast proliferation, and suppressing osteoclast differentiation and osteoclastic bone resorption. Therefore, the protein material is useful for prevention and treatment of various bone diseases, such as osteoporosis, fracture, rheumatism, and arthritis.

BACKGROUND ART In recent years, various bone diseases, such as osteoporosis, fracture, and backache have increased on a global basis along with aging of society and the like, and have become a serious social problem. These diseases are caused by insufficient calcium intake, depression of calcium absorption ability, e imbalance after menopause, and the like. It is considered that increase the body bone mass as much as possible by ting the osteoblast and bone formation from the early stage of life, and increase the maximum bone mass and the bone strength (bone y + bone quality) is effective in preventing various bone diseases, such as osteoporosis, fracture, and backache. Note that the term “bone quality” refers to the bone microstructure, metabolic turnover, racture, and calcification. It is thought that various bone diseases, such as osteoporosis, fracture, and backache may be prevented by suppressing osteoclastic bone resorption. Bones are repeatedly resorbed and formed in a balanced manner (remodeling). However, s bone diseases, such as osteoporosis, fracture, and he may occur when bone resorption s bone formation due to a change SNOW—191 in hormone balance after menopause, and the like. ore, bones can be strengthened by suppressing osteoclastic bone resorption and maintaining the bone strength at a constant level.

In view of the above situation, a drug, food, drink, feed, or the like in which a calcium salt, such as calcium ate, calcium phosphate, or calcium lactate or a natural calcium product, such as whey calcium, bovine bone , or ll is added individually, has been stered in order to strengthen bones. A drug, food, drink, feed, or the like that contains such a calcium product together with a substance having a calcium absorption-promoting effect, such as casein phosphopeptide or accharide has also been used to strengthen bones. r, the calcium absorption rate is 50% or less, when a food or drink that contains a- calcium salt or natural calcium product is administered, and the large part of the calcium administered may be rged from the body without being absorbed. Moreover, even if calcium is absorbed into the body, it does not necessarily exhibit the bone metabolism-improving efiect or a bone strengthening effect, since the affinity to bones may differ according to its form or the type of nutritional ingredient administered together. An estrogen product, an active Vitamin D3 product, a vitamin K2 product, a bisphosphonate t, a calcitonin product, and the like have been known as a drug for treating osteoporosis or strengthening bones, and new drugs such as an anti-RANKL antibody have been also developed. However, these drugs may have side effects such as buzzing in the ear, a headache, or loss of appetite. Moreover, the above substances are in a situation that they cannot be added to a food or drink at present from the viewpoint of safety, cost, and the like. Therefore, in light of the nature of various bone diseases, such as osteoporosis, re, and backache, development of such a bone-strengthening agent, food, drink, or feed that can be administered orally for a long time, increases the bone strength by promoting bone formation and suppressing bone SNOW-191 resorption, and may be ed to have the effect of preventing or treating the various bone diseases has been desired.

There are several food materials that intends to improve the bone strength, for e, it has been reported that a basic protein derived from milk or a peptide fraction of an tically degraded product thereof exhibits osteoblast proliferation activity, osteoclastic bone tion suppression activity, and thus a trengthening effect (see Patent Document 1). It has also been reported that angiogenin and cystatin, contained in a basic protein fraction derived from milk, ndently have a function to improve the bone lism (see Patent nts 2 and 3).

PRIOR-ART DOCUMENT PATENT DOCUMENT [Patent Document 1] JP-A-H08-151331 [Patent Document 2] JP-A-H10-7585 [Patent Document 3] JP-A281587 SUMMARY OF THE INVENTION The invention relates to provide a novel protein material that is safe, promotes osteoblast proliferation while suppressing osteoclast differentiation and osteoclastic bone resorption by administering daily, and thus can strengthen bones.

The invention relates to provide a bone-strengthening drug, food, drink, or feed that is useful for prevention and treatment of various bone diseases, such as osteoporosis, fracture, rheumatism, and arthritis by administering orally.

SNOW-191 The present inventors have found that the effects of ively promoting osteoblast proliferation, and suppressing osteoclast differentiation and osteoclastic bone resorption can be obtained by administering a protein material that includes angiogenin and/or angiogenin hydrolysate in a specific amount, and r includes cystatin and/or cystatin hydrolysate in a ic mass ratio with respect to angiogenin and/or angiogenin hydrolysate. This finding has led to the tion of the invention.

Specifically, the invention provides the following aspects: (1) A protein al comprising angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg of the protein material and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or enin hydrolysate of 0.003 to 0.6. (2) A food, drink, or feed including the protein material according to (1). (3) A bone-strengthening agent including the protein material according to (1) as an active ingredient. (4) A method of strengthening bones including administering the protein material according to (1) in amount of 5 mg/day or more. (4a) Use of (i) enin and/or angiogenin ysate and (ii) in and/or cystatin hydrolysate in the manufacture of a medicament for the strengthening of bones, wherein the angiogenin and/or angiogenin hydrolysate is present in an amount of 2 to mg/100 g of medicament and wherein the cystatin and/or cystatin hydrolysate is present in a ratio of 0.003 to 0.6 to the mass of angiogenin and/or angiogenin hydrolysate. (4b) Use of (i) angiogenin and/or enin hydrolysate and (ii) cystatin and/or cystatin hydrolysate in the manufacture of a medicament for the treatment or prevention of osteoporosis, fracture, tism and/or arthritis, wherein the angiogenin and/or angiogenin hydrolysate is present in an amount of 2 to 15 mg/100 g of medicament and wherein the cystatin and/or cystatin hydrolysate is present in a ratio of 0.003 to 0.6 to the mass of angiogenin and/or angiogenin hydrolysate. (5) A method of preparing the protein material according to (1), including the following steps of 1) to 3): 1) preparing angiogenin and/or angiogenin hydrolysate; 2) ing cystatin and/or cystatin hydrolysate; and 3) mixing the cystatin and/or cystatin hydrolysate according to above 2) and the angiogenin and/or angiogenin hydrolysate according to above 1) in the mass ratio of the in and/or cystatin hydrolysate to the angiogenin and/or enin hydrolysate of 0.003 to 0.6. (6) A method of producing the protein material according to (1), SNOW-191 comprising a step of extracting a fraction containing angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate from milk and/or a material derived from milk in the mass ratio to the angiogenin and/or the angiogenin hydrolysate of 0.003 to 0.6. (7) The method ing to (6), further including another step of enzymatically degrading the angiogenin and/or the cystatin contained in the on.

EFFECTS OF THE INVENTION The protein material of the invention exhibits a remarkable trengthening effect through the function of promoting last proliferation, and suppressing osteoclast differentiation and osteoclastic bone resorption. The drug, food, drink, or feed of the invention strengthens bones, and is useful for prevention and treatment of various bone diseases, such as osteoporosis, fracture, rheumatism, and arthritis.

EMBODIMENTS FOR CARRYING OUT THE INVENTION A protein material of the invention is characterized in that the protein material includes angiogenin and/or enin hydrolysate in a specific amount, and further includes cystatin and/or cystatin hydrolysate in a specific mass ratio with respect to angiogenin and/or angiogenin hydrolysate.

The protein material of the invention may be a mixture obtained by mixing a fraction containing angiogenin and/or angiogenin hydrolysate and a fraction containing cystatin and/or in hydrolysate in a specific mass ratio, a material prepared by ting a fraction containing angiogenin and/or enin ysate and cystatin and/or cystatin hydrolysate in a specific mass ratio from milk or a al derived from milk, such as skim milk or whey, or the like. The protein material of the invention SNOW—191 may also include a material prepared by enzymatically degrading angiogenin and/0r cystatin.

When preparing the protein al of the invention by mixing a fraction containing angiogenin and/0r angiogenin hydrolysate and a fraction containing cystatin and/or cystatin hydrolysate, a fraction prepared from milk of a mammal, such as human, cow, buffalo, goat, or sheep, a fraction produced by genetic engineering, a on purified from blood or an internal organ, or the like may be used as the fraction containing angiogenin and/or angiogenin hydrolysate and the fraction containing cystatin and/or cystatin hydrolysate. A commercially available purified angiogenin or in reagent may also be used. In this case, the protein material of the invention may be prepared by adjusting the mass ratio of cystatin and/or cystatin hydrolysate to angiogenin and/0r angiogenin hydrolysate.

A product obtained by enzymatically ing the above on containing enin, the angiogenin reagent, the fraction containing cystatin, the in reagent, or the like using one or more proteases may be used as angiogenin hydrolysate or cystatin hydrolysate.

When preparing the protein material of the invention by directly extracting a on which contains angiogenin and/or angiogenin hydrolysate and cystatin and/or cystatin hydrolysate in a specific mass ratio from milk or a material derived from milk, such as skim milk or whey, for example, milk or a material derived from milk may be brought into contact with a cation-exchange resin, and then milk-derived proteins adsorbed on the resin may be eluted at a salt concentration of 0.1 to 2.0 M, desalted and trated using a reverse s membrane, an electrodialysis membrane, an ultrafiltration membrane, a microfiltration membrane, or the like, afler that ally subjected to limited degradation to a lar weight of 8000 or less using a protease, SNOW-191 such as trypsin, pancreatin, chymotrypsin, pepsin, papain, rein, cathepsin, thermolysin, or V8 se. When subjecting to limited degradation using a protease, it is preferable that the lower limit of the molecular weight is 500 or more. The protein material thus obtained may be dried by freeze-drying, spray drying, or the like.

When subjecting the protein material of the ion to LC/MS/MS is, after subjecting to modification and limited degradation under reducing ion using a digestive enzyme in the usual manner in order to carry out a proteome analysis of the protein material, it was confirmed that the protein material contained at least one of protein such as usl-casein, as2-casein, in, or K-casein, and proteolysis product thereof other than angiogenin and/or angiogenin hydrolysate and in and/or cystatin hydrolysate.

The protein material of the invention includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and includes cystatin and/0r in hydrolysate in the mass ratio of 0.003 to 0.6 to angiogenin and/or angiogenin hydrolysate.

As shown in the test examples described below, when the mass ratio of cystatin and/or cystatin hydrolysate to angiogenin and/or angiogenin hydrolysate is 0.003 to 0.6, the bone-strengthening effect can be obtained more effectively than the case of ingesting angiogenin and/or angiogenin hydrolysate or cystatin and/or cystatin hydrolysate separately.

Note that, for reference only, the t of angiogenin and/or angiogenin hydrolysate in cow milk is about , and the mass ratio of in and/or cystatin hydrolysate t0 angiogenin and/or angiogenin hydrolysate in cow milk is about 2. The content of angiogenin and/or angiogenin hydrolysate in a whey protein concentrate (WPC) is about 0.1%, and the mass ratio of cystatin and/or cystatin hydrolysate to SNOW—191 angiogenjn and/or angiogenin hydrolysate in a whey protein concentrate is about 3.

The protein material of the invention may be prepared as a bone-strengthening agent by appropriately adding the protein material as an active ingredient. The protein material of the invention may be used directly as a bone—strengthening agent. When formulating as a bone-strengthening agent, it may be possible to mix a raw material or the like that is usually used for drugs, food, drink, and feed, such as a saccharide, a lipid, a protein, a vitamin, a l, or a flavor, and it may be also le to formulate into a powdered drug, granules, a tablet, a capsule, a drinkable preparation, or the like in the usual manner. The protein material of the invention may be used together with another ingredient that also exhibits a bone-strengthening effect, such as calcium, vitamin D, n K, or isoflavone.

The protein material of the invention can strengthen bones when administered orally in an amount of 5 mg or more per kg of body weight, as shown in the animal experiments described below. Since the intake for this experimental animal corresponds to the intake for adults in terms of blood drug concentration (see Mitsuyoshi Nakajima (1993), “Yakkou Hyoka Vol. 8”, Hirokawa—Shoten Ltd., pp. 2—18), it is expected that the bone-strengthening effect is obtained, and especially various bone diseases, such as osteoporosis, fracture, tism, and arthritis can be prevented or treated by ingesting the protein material of the invention in an amount of 5 mg/day or more per an adult. Therefore, when mixing to a bone-strengthening agent or the like, the protein al may be added thereto so as to ingest the above necessary .

The protein material of the invention may be added to a normal food or drink, such as yogurt, beverage, wafer, or dessert). In this case, the n material of the ion is preferably added in an amount of 0.25 to 1000 mg per 100 g of the food or drink depending on the form of the food or drink. It is expected that the SNOW-191 bone—strengthening effect can be obtained by keeping the above mixing amount. The protein material of the invention may also be added to a feed, such as livestock feed or pet food to prepare a bone-strengthening feed. In this case, it is preferable to add the protein material of the ion in an amount of 0.25 to 1000 mg per 100 g of the feed.

When the protein al of the ion is prepared and used in the form of a drug, food, drink, or feed, the protein material of the invention may be used by ding or dissolving in deionized water, and mixing with stirring. The stirring/mixing conditions are not particularly limited as long as the protein material is uniformly mixed. It is also possible to mix with stirring using an ultra-disperser, a TK-homomixer, or the like.

The solution of the n material may optionally be ed or concentrated using a reverse osmosis membrane or the like, or freeze-dried so that the solution can be easily used for a drug, food, drink, or feed.

Notably, it was confirmed that the protein material of the invention maintains the bone—strengthening activity even when the protein material is subjected to sterilization treatment that is commonly used in the production of a drug, food, drink, or feed. The protein material may be subjected to dry-heat sterilization when the protein material is used as a powder. The protein material of the invention may be used for a drug, food, drink, or feed in various forms, such as liquid, gel, powder, or granular. [001 8] The invention is further described below in more detail by way of reference examples, examples, and test examples. Note that the following examples are intended for illustration purposes only, and should not be ued as limiting the invention. nce Example 1 ation (1) of angiogenin fraction SNOW—191 A column filled with 30 kg of cation~exchange resin nated Chitopearl; manufactured by Fuji Spinning Co., Ltd.) was thoroughly washed with deionized water, and 1000 liters of eurized skim milk (pH 6.7) was then applied to the column.

After thoroughly washing the column with deionized water, the ed protein was eluted with a linear gradient of 0.1 to 2.0 M sodium chloride. The elution fraction containing angiogenin was fractionated using an S—Sepharose cation-exchange tography (manufactured by Amersham Bioscientific), and the resulted angiogenin-containing fraction was heat—treated at 90°C for 10 minutes, and fuged to remove a precipitate. The angiogenin—containing fraction was fiirther subjected to gel filtration chromatography (column: Superose 12). The eluate obtained was desalted using a e osmosis membrane, and the desalted eluate was freeze-dried to obtain 16.5 g of an angiogenin fraction having an angiogenin purity of 90%. These successive operations were repeated 30 times.

Reference Example 2 Preparation (2) of angiogenin fraction A column filled with 10 kg of Heparin Sepharose (manufactured by GE Healthcare) was thoroughly washed with deionized water, and 500 liters of unpasteurized skim milk (pH 6.7) was then applied to the column. After thoroughly washing the column with a 0.5 M sodium chloride solution, the absorbed protein was eluted with a 1.5 M sodium chloride solution. The eluate was desalted using a e osmosis membrane, and the desalted eluate was -dried to obtain 18 g of an angiogenin on having an angiogenin purity of 5%. The above successive operations were repeated 50 times.

Reference Example 3 Preparation of cystatin fraction SNOW-191 100,000 liters of a 5% whey protein solution was heat-treated at 90°C for 10 minutes, and a precipitate was removed by centrifugation. A column was filled with a carrier ed by binding carboxymethylated papain t0 Tresyl—Toyopearl (manufactured by Tosoh Corporation). After equilibration with a 0.5 M sodium de solution, the above Whey protein solution was applied to the column. The column was then sequentially washed with a 0.5 M sodium chloride solution and a 0.5 M sodium chloride on containing Tween 20 . After that, a cystatin-containing fraction was eluted with a 20 mM acetic acid-0.5 M sodium chloride solution. ' The eluted fraction was immediately neutralized with a 1 M sodium ide solution. The eluate was then desalted using a reverse osmosis membrane, and the desalted eluate was freeze-dried to obtain 9.6 g of a cystatin fraction having a cystatin purity of 90%. The above successive operations were repeated 20 times.

Example 1 Five point three zero milligrams (5.30 mg) ofthe angiogenin fraction obtained in Reference e 1, 84.67 mg of the enin fraction obtained in Reference Example 2, and 0.03 mg of the cystatin fraction obtained in Reference Example 3 were mixed to prepare a protein material (example product 1) in which the t of angiogenin and/or angiogenin hydrolysate was 10 mg/IOO mg, and the mass ratio of in and/0r cystatin hydrolysate to angiogenin and/or angiogenin ysate was 0.003.

Example 2 Five point three five milligrams (5.35mg) of the angiogenin fraction obtained in Reference Example 1, 83.65 mg of the angiogenin fraction obtained in Reference Example 2, and 1.00 mg of the cystatin fraction obtained in Reference Example 3 were mixed to prepare a protein material (example product 2) in which the content of SNOW-191 - angiogenin and/or angiogenin hydrolysate was 10 mg/100 mg, and the mass ratio of cystatin and/or cystatin hydrolysate to angiogenin and/or angiogenin hydrolysate was 0.1.

Example 3 Five point six five milligrams (5.65 mg) of the angiogenin fraction ed in Reference Example 1, 78.35 mg of the angiogenin fraction obtained in Reference e 2, and 6.00 mg of the cystatin fraction obtained in Reference Example 3 were mixed to prepare a protein material (example product 3) in which the content of angiogenin and/0r enin hydrolysate was 10 mg/IOO mg, and the mass ratio of cystatin and/or cystatin ysate to angiogenin and/or angiogenin hydrolysate was 0.6.

Comparative Example 1 Five point thee zero rams (5.30 mg) of the angiogenin fraction obtained in Reference Example 1, 84.68 mg of the angiogenin on obtained in Reference Example 2, and 0.02 mg of the cystatin fraction obtained in Reference e 3 were mixed to e a protein material (comparative example product 1) in which the content of angiogenin and/0r angiogenin hydrolysate was 10 mg/l 00 mg, and the mass ratio of cystatin and/or in hydrolysate to angiogenin and/or angiogenin hydrolysate was 0.002.

Comparative Example 2 Five point six eight milligrams (5.68 mg) of the angiogenin fraction obtained in nce Example 1, 77.82 mg of the angiogenin fraction obtained in Reference Example 2, and 6.50 mg of the cystatin fraction obtained in Reference Example 3 were mixed to prepare a protein material (comparative example product 2) in which the content of angiogenin and/0r angiogenin hydrolysate was 10 mg/100 mg, and the mass ratio of cystatin and/0r cystatin hydrolysate to angiogenin and/0r angiogenin hydrolysate was 0.65.

Test Example 1 The osteoblast proliferation effect, the suppressive efi‘ect on osteoclastic bone resorption, and the suppressive efiect on osteoclast differentiation of the example products 1 to 3 and the comparative example products 1 and 2 were determined.

The osteoblast eration effect was determined as described below. An osteoblastic cell line (MC3T3-E1) was seeded on a 96-well cell e plate at a y of 2X103 cells/well, and cultured for 24 hours using an a—MEM medium (manufactured by GIBCO) supplemented with 10% fetal bovine serum (FBS). After the medium was tely removed, 90 ul of a PBS free a-MEM medium, and 10 pl of a solution ning any of the example products 1 to 3 and the comparative example products 1 and 2 is added to each well. The cells were further cultured for 24 hours. Afier the addition of bromodeoxyuridine (BrdU) which was included in the Cell Proliferation Kit (manufactured by GE Healthcare), the cells were cultured for 2 hours, and reacted with ' a peroxidase-labelled anti—BrdU antibody. After the addition of 3,3’,5,5’-tetramethy1benzidine (substrate), the osteoblast proliferation activity was determined by measuring the amount of BrdU uced into the cells through measuring the absorbance at 450 nm. The osteoblast proliferation activity was determined to be positive when the absorbance at 450 nm was significantly higher than that of a group ol), in which none of the example products 1 to 3 and the comparative example products 1 and 2 were added to the medium.

The suppressive effect on osteoclastic bone resorption was determined as described below. The tibia and the thighbone were taken out from a rabbit (5 days old).

SNOW-191 After removing the soft tissue, these bones were mechanically chopped and the total bone marrow cells containing the osteoclasts were dispersed in an u—MEM medium supplemented with 5% FBS, and then seeded on the wells of a crystalline calcium phosphate plate (manufactured by Corning) at a density of l><106 cells/well. The medium was completely removed at 2 hours after starting the culture, and 180 pl of an u—MEM medium supplemented with 5% FBS, and 20 pl of a solution containing any of the example products 1 to 3 and the comparative e products 1 and 2 was added to each well. The cells were cultured for 72 hours. After removing the cells by addition of a 5% sodium hypochlorite solution, tion pits formed on the wells of the calcium phosphate plate were photographed using a stereoscopic microscope, and the area thereof was measured by image analysis to determine the suppressive effect on osteoclastic bone resorption (Takeshi Seno et al., “Manual of selected cultured cell lines for bioscience biotechnology”, pp. 199-200, 1993). The suppressive activity against osteoclastic bone resorption was determined to be positive when the pit area was cantly smaller than that of a group (control), in which any of the example products 1 to 3 and the comparative example products 1 and 2 was not added to the medium.

The suppressive effect on last entiation was determined as described below. The bone marrow cells collected from the thighbone of a ddy mouse (7 or 8 weeks old, male) were seeded on a 96-well plate at a y of 4><104 well, and ed in 200 pl of a a-MEM medium supplemented with 10% FBS and M—CSF (25 ng/ml) at 37°C and 5% C02. After the medium was completely removed on 2 days after starting the culture, 180 pl of a a—MEM medium supplemented 10 % FBS, RANKL (5 ng/ml) and M—CSF (25 ng/ml), and 20 u] of a solution containing any of the example products 1 t0 3 and the comparative e products 1 and 2 was added to each well, and the cells were cultured under the condition of 37°C and 5% C02 for 2 SNOW-191 days. After changing the medium, the cells were further cultured for 1 day. At the completion of the culture, the culture solution was d, washed with PBS, and treated with an acetone-ethanol (1:1) solution for 1 minute to fix the cells. After that, 1.5 rug/ml of a disodium p—nitrophenylphosphate-ZO mM sodium te-SO mM citrate buffer (pH 4.5) was added (100 til/well), and reacted at room temperature for 30 minutes, and then, a 1 M sodium hydroxide solution (50 ul/well) was added to terminate the reaction. The absorbance at 405 nm was measured, and taken as an index of osteoclast entiation/mutation. The suppressive activity against last differentiation was determined to be positive when the absorbance at 405 nm of group adding example products 1 to 3 or the comparative example products 1 or 2 was significantly lower than that of a group (control), in which any product of example products 1 to 3 and the comparative example products 1 and 2 was not added to the medium.

The results are shown in Table 1.

TABLE 1 osteoblast suppressive activity suppressive activity proliferation against osteoclastic t osteoclast activity bone resorption differentiation EEee e Eeeeee EeeEe comparative negative ve positive exam le 1 Comparative e positive example 2 p negative As shown in Table l, the example products 1 to 3 which correspond to the protein material of the invention exhibited positive activity in all cell assays. The SNOW-191 comparative example products 1 and 2 also exhibited ve ty in the some cell assays, but there were one cell assay that exhibited negative activity.

Example 4 A column (diameter: 4 cm, height: 30 cm) filled with 400 g of cation-exchange resin (Sulfonated Chitopearl; manufactured by Fuji Spinning Co., Ltd.) was thoroughly washed with deionized water, and 40 liters of unpasteurized skim milk (pH 6.7) was applied to the column at a flow rate of 25 ml/min. After thoroughly washing the column with deionized water, proteins ed on the resin were eluted using a 0.02 M carbonate buffer (pH 7.0) containing 0.78 M sodium chloride. The eluate was desalted using a reverse osmosis membrane, and the ed eluate was freeze-dried to obtain 18 g of a powdery protein material (example product 4). The protein material contained angiogenin and/or angiogenin hydrolysate in an amount of 2 rug/100 mg, and the mass ratio of cystatin and/or cystatin hydrolysate to angiogenin and/or angiogenin hydrolysate was 0.5. The protein al may be used directly as a trengthening agent or an active ingredient of a bone-strengthening agent. As a result of proteome analysis, it was found that the protein material contained ed product of B-casein and degraded product of K—casein.

Example 5 A column (diameter: 20 cm, height: 100 cm) filled with 30 kg of cation-exchange resin (SP Toyopearl; manufactured by Tosoh Corporation) was thoroughly washed with deionized water, and 3 t of whey (pH 6.2) which was terilized at 75°C for 15 minutes was applied to the column at a flow rate of 10 1/min. After thoroughly washing the column with deionized water, proteins adsorbed on the resin were eluted using a 0.1 M e buffer (pH 5.7) containing 0.68 M sodium chloride. The eluate was desalted using an electrodialysis membrane, and the desalted SNOW-191 eluate was freeze—dried. The above successive operations were repeated 20 times to obtain 3.3 kg of a powdery protein material (example product 5). The n material contained angiogenin and/or angiogenin hydrolysate in an amount of 15 mg/100 and the mass ratio of in and/0r cystatin hydrolysate to angiogenin and/0r angiogenin hydrolysate was 0.01. The protein material may be used directly as a bone-strengthening agent or an active ingredient of a bone-strengthening agent. As a result of me analysis, it was found that the protein material contained degraded products of asl-casein and K—casein.

Example 6 Four grams (4 g) of n material of the e t 4 was dissolved in 800 m1 of water. After the addition of pancreatin (manufactured by Sigma), which was a se, at the final concentration of 0.02 wt%, and then the mixture was subjected to enzymatic treatment at 37°C for 8 hours. After inactivating the protease through heat-treatrnent at 90°C for 5 minutes, the mixture was freeze-dried to obtain 3.2 g of a protein material (example t 6). The protein material thus obtained contained angiogenin hydrolysate in an amount of 2.0 mg/100 mg, and the mass ratio of cystatin hydrolysate to angiogenin hydrolysate was 0.45, and the molecular weight ofthe protein material was 8000 or less. Therefore the protein material may be used directly as a bone-strengthening agent'or an active ingredient of a bone-strengthening agent. As a result of proteome analysis, it was found that the protein material contained degraded products of B-casein and K-casein.

Example 7 Four grams (4 g) of protein material of the e product 5 was dissolved in 800 ml of water. After the addition of trypsin (manufactured by Sigma), which was a protease, so as to obtain at the final tration of 0.03 wt%, the mixture was SNOW-191 subjected to enzymatic treatment at 37°C for 8 hours. After inactivating the protease through heat-treatment at 90°C for 5 minutes, the mixture was -dried to obtain 3.0 g of a protein material (example t 7). The protein material thus ed contained angiogenin hydrolysate in an amount of 14 mg/100 mg, and the mass ratio of cystatin hydrolysate to angiogenin hydrolysate in the protein material was 0.015, and the molecular weight of the protein material was 8000 or less. Therefore, the protein material may be used directly as a bone-strengthening agent or an active ingredient of a bone—strengthening agent. As a result of proteome analysis, it was found that the protein material contained degraded products of asl-casein and K—casein.

Comparative Example 3 Ten milligrams (10 mg) of the cystatin fraction obtained in Reference e 3 and 100 mg of the protein material of the example product 4 were mixed to prepare a protein al (comparative example product 3) in which the content of enin and/or angiogenin hydrolysate was 1.8 mg/100 mg, and the mass ratio of cystatin and/or cystatin hydrolysate t0 angiogenin and/or angiogenin hydrolysate was 5.

Comparative Example 4 One gram (1 g) of the angiogenin fraction obtained in Reference Example 1 and 2 g of the protein material of the example product 5 were mixed and dissolved in 800 m1 of water. After the addition of trypsin (manufactured by , which is a protease at the final concentration of 0.02 wt%, the mixture was subjected to enzymatic treatment at 37°C for 12 hours. After inactivating the protease through reatment at 90°C for 5 minutes, the mixture was freeze-dried to obtain 2.8 g of a protein material (comparative e product 4). The protein material thus obtained contained angiogenin hydrolysate in an amount of 39 mg/100 mg, and the mass ratio of cystatin hydrolysate to angiogenin hydrolysate was 0.0025.7 SNOW—1 91 [003 8] Comparative Example 5 A column (diameter: 5 cm, height: 5 cm) filled with 100 g of cation-exchange resin (CM Sepharose FF; manufactured by GE Healthcare) was thoroughly washed with deionized water, and 40 liters of unpasteurized skim milk (pH 6.7) was applied to the column at a flow rate of 40 mllmin. After thoroughly washing the column with deionized water, proteins adsorbed on the resin were eluted using a 0.02 M ate buffer (pH 6.8) containing 0.98 M sodium chloride. The eluate was desalted using a reverse osmosis membrane, and the desalted eluate was -dried to obtain 20 g of a powdery protein material (comparative example product 5). The protein material contained angiogenin and/or angiogenin hydrolysate in an amount of 1.5 mg/100 and the mass ratio of cystatin and/or cystatin hydrolysate t0 angiogenin and/or angiogenin hydrolysate was 0.001.

Test Example 2 Each bone-strengthening efl'ect of the example products 4 and 5 and the comparative example products 3 and 5 were determined by animal experiments.

C3H/HeJ mice (5 weeks old, male) were used for the animal experiments. After 1 week acclimation, the mice were divided into five groups (6 roup). The mice were orally administered the example products 4 or 5 or the ative example products 3 or 5 in an amount of 5 mg per 1 kg of body weight once a day for 4 weeks using a tube. The control group was not administrated any e ts 4 and 5 and the comparative example products 3 and 5 were not administered. After completion of administration (fourth week), the bone density of the right tibia of each mouse was measured using a CT (manufactured by Rigaku Corporation). The results are shown in Table 2.

SNOW-191 TABLE 2 As shown in Table 2, the groups that were orally administered the e . product 4 or 5 that were the protein material of the invention showed a significant increase in bone density as compared with the control group and the groups that were orally administered the comparative example product 3 or 5.

Test Example 3 Each bone-strengthening effect of the example products 6 and 7 and the comparative example products 4 and 5 was determined by animal experiments.

Forty—eight SD rats (51 weeks old, female) were used for the animal experiments.

The rats were divided into six groups (8 rats/group). Five groups underwent ovariectomy, and the remaining one group was subjected to sham surgery. After a 4-week recovery , the rats underwent ovariectomy were orally stered the example products 6 or 7 or the comparative example ts 4 or 5) in an amount of 5 mg per 1 kg of rat weight once a day for 16 weeks using a tube. The control group was not administrated any example ts 6 and 7 and the comparative. example products 4 and 5. After a 4-week recovery period, the rats underwent sham surgery were fed for 16 weeks in the same manner as the control group. After completion of administration (sixteenth week), the bone density of the right tibia of each rat was SNOW-191 measured using a micro-CT (manufactured by Rigaku Corporation). The results are shown in Table 3.

TABLE 3 As shown in Table 3, the groups that were orally administered the example product 6 or 7 that was the protein material of the invention showed a significant se in bone density as compared with the control group and the groups that were orally stered the comparative example product 4 or 5. Moreover, the bone y approached that ofthe sham surgery group.

Example 8 Preparation of bone-strengthening liquid nutritional supplement Five grams (5 g) of the n material of the example product 4 was ved in 4995 g of deionized water. The solution was stirred at 6000 rpm for 30 minutes using a TK-homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo co., ltd.) to obtain a solution containing the example product 4 in an amount of 100 mg/l 00 g. Then, 4.0 kg of casein, 5.0 kg of a soybean protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 18.0 kg of dextrin, 6.0 kg of a mineral mixture, 1.95 kg of a vitamin mixture, 2.0 kg of an emulsifying agent, 4.0 kg of a stabilizer, and 0.05 kg of essence were added to 5.0 kg of the solution. The mixture was charged in a retort pouch (200 ml) and sterilized at 121°C for 20 minutes using a retort sterilizer -1 pressure vessel, RCS-4CRTGN; manufactured by Hisaka Works, Ltd.) to produce 50 kg of a bone—strengthening liquid nt composition. Any precipitation was observed, and no abnormal flavor was felt in the bone—strengthening liquid nutrient composition thus Example 9 Preparation of bone-strengthening gel—like food Two grams (2 g) of the protein material of the example product 5 was dissolved in 708 g of deionized water. The solution was stirred and mixed using an ultra-disperser (ULTRA—TURRAX T—25; ctured by IKA Japan) at 9500 rpm for minutes. 40 g sorbitol, 2 g of a sour agent, 2 g of essence, 5 g of pectin, 5 g of a whey protein concentrate, 1 g of calcium lactate, and 235 g of deionized water were added to the solution. After stirring and mixing, the mixture was charged into a 200 ml cheer pack, and sterilized at 85°C for 20 minutes, and the pack was sealed to obtain five packs (200 g) of a bone-strengthening gel—like food. Any precipitation was observed, and no abnormal flavor was felt in the bone-strengthening gel-like food thus obtained.

Example 10 ation of bone-strengthening drink Two grams (2 g) of an er was dissolved in 706 g of deionized water, and 4 g of the protein material of the example product 6 was dissolved in the solution. The solution was stirred and mixed using an disperser (ULTRA—TURRAX T-25; manufactured by IKA Japan) at 9500 rpm for 30 minutes. After the addition of 100 g SNOW-191 of maltitol, 20 g of d starch syrup, 2 g of essence, and 166 g of deionized water, the mixture was charged into a 100 m1 glass bottle. After sterilized at 95°C for 15 seconds, the 'bottle was closely sealed to obtain ten bottles (100 ml) of a bone—strengthening drink. Any precipitation was observed, and no abnormal flavor was felt in the bone—strengthening drink thus obtained.

Example 11 Preparation of bone—strengthening feed Two ams (2 kg) of the protein material of the example product 7 was dissolved in 95 kg of deionized water. The solution was stirred and mixed using a TK—homomixer (MARK II 160; ctured by PRIMIX ation) at 3600 rpm for 40 minutes to obtain a solution containing the example t 7 in an amount of 2 g/100 g. Then, 12 kg of soybean meal, 14 kg of powdered skim milk, 4 kg of soybean oil, 2 kg of corn oil, 23.2 kg of palm oil, 14 kg of corn starch, 9 kg of flour, 2 kg of bran kg of a vitamin mixture, 2.8 kg of ose, and 2 kg of a mineral mixture were added to 10 kg of the solution. The mixture was sterilized at 120°C for 4 minutes to obtain 100 kg of a bone-strengthening dog food.

Example 12 Preparation of bone—strengthening agent (tablet) The raw materials were mixed in the ratio shown in Table 4. Then, 1 g of the mixture was formed and tableted in the usual manner to prepare a bone-strengthening agent.

TABLE 4 Hydrous crystalline glucose 92.5 % (wt %) Protein material (example product 1) SNOW-191 Mineral e 5.0 % Sugar ester 1.0 % Essence 0.5 % SNOW-191

Claims (10)

1. A protein material comprising angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg of the protein material and cystatin and/or cystatin ysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.003 to 0.6.

2. A food, drink, or feed sing the protein material according to claim 1.

3. A bone-strengthening agent comprising the protein al according to claim 1 as an active ingredient.

4. Use of (i) angiogenin and/or angiogenin hydrolysate and (ii) cystatin and/or cystatin hydrolysate in the cture of a medicament for strengthening bones, wherein the angiogenin and/or angiogenin hydrolysate is present in an amount of 2 to 15 mg/100 g of medicament and wherein the cystatin and/or cystatin hydrolysate is present in a ratio of 0.003 to 0.6 to the mass of angiogenin and/or angiogenin hydrolysate.

5. Use of (i) angiogenin and/or enin hydrolysate and (ii) cystatin and/or cystatin hydrolysate in the manufacture of a medicament for the treatment or tion of osteoporosis, fracture, rheumatism and/or arthritis, wherein the angiogenin and/or angiogenin hydrolysate is present in an amount of 2 to 15 mg/100 g of medicament and wherein the cystatin and/or cystatin hydrolysate is present in a ratio of 0.003 to 0.6 to the mass of angiogenin and/or angiogenin hydrolysate.

6. Use ing to claim 4 or 5 wherein the medicament is for administration at an amount of 5 mg/day or more.

7. Use according to any one of claims 4 to 6 wherein the medicament is a n material.

8. A method of preparing the protein material according to claim 1, comprising following steps 1) to 3): 1) preparing angiogenin and/or angiogenin hydrolysate; SNOW-191 2) preparing in and/or cystatin hydrolysate; and 3) mixing the cystatin and/or cystatin hydrolysate according to above 2) and the angiogenin and/or angiogenin hydrolysate according to above 1) in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.003 to 0.6.

9. A method of producing the protein material according to claim 1, comprising a step of extracting a fraction containing angiogenin and/or angiogenin hydrolysate and cystatin and/or in hydrolysate from milk and/or a material derived from milk in the mass ratio to the enin and/or the angiogenin hydrolysate of 0.003 to 0.6.

10. The method according to claim 9, further comprising another step of enzymatically ing the angiogenin and/or the cystatin contained in the fraction.